Research Roundup


Debbie Rigby takes a look at the latest in research news Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduce elevated blood glucose levels and induce weight loss. Randomised trials support the superior efficacy of semaglutide over other GLP-1 RAs

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Show

Forgot Password?Why do I need to login & stay in?

Previous Prescribers ‘lack clarity’ on 60-day prescribing
Next Petition calls for 60-day U-turn